The high need for trials assessing functional outcome after stroke rather than stroke prevention with GLP-1 agonists and DPP-4 inhibitors

Keywords: Glucagon-like peptide 1 receptor, Dipeptidyl peptidase-4 inhibitors, Stroke, Diabetes

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	CARDIOVASCULAR DIABETOLOGY 2018-02, Vol.17 (1), p.32-32, Article 32
Hauptverfasser:	Darsalia, Vladimer, Larsson, Martin, Klein, Thomas, Patrone, Cesare
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Care and treatment Clinical Trials as Topic Diabetes Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Diabetes Mellitus, Type 2 - metabolism Diabetics Diagnosis Dipeptidyl Peptidase 4 - metabolism Dipeptidyl peptidase-4 inhibitors Dipeptidyl-Peptidase IV Inhibitors - adverse effects Dipeptidyl-Peptidase IV Inhibitors - therapeutic use Disability Evaluation Disease Models, Animal Dosage and administration Endpoint Determination Evidence-Based Medicine Glucagon-like peptide 1 receptor Glucagon-Like Peptide-1 Receptor - agonists Glucagon-Like Peptide-1 Receptor - metabolism Health aspects Humans Hyperglycemia Hypoglycemic agents Incretins - adverse effects Incretins - therapeutic use Licensing, certification and accreditation Recovery of Function Stroke Stroke - diagnosis Stroke - drug therapy Stroke - epidemiology Stroke - metabolism Translational Medical Research Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Keywords: Glucagon-like peptide 1 receptor, Dipeptidyl peptidase-4 inhibitors, Stroke, Diabetes
ISSN:	1475-2840 1475-2840
DOI:	10.1186/s12933-018-0674-3